Actively Recruiting

Age: 19Years +
MALE
NCT06236789

Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer

Led by Yonsei University · Updated on 2024-02-01

60

Participants Needed

1

Research Sites

521 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Prostate cancer is the 2nd most common cancer in men worldwide. Based on the results of several recent clinical trials, systemic treatments including hormone inhibitors, docetaxel, cabazitaxel, and PARP inhibitors are being used as standard treatment for patients with metastatic castration-resistant prostate cancer. However, there is insufficient research on salvage therapy for patients with metastatic castration-resistant prostate cancer who have failed standard treatment. In this study, the investigators will evaluate the effectiveness and safety of ifosfamide in castration-resistant prostate cancer by analyzing the treatment outcomes of patients who received ifosfamide/mesna treatment as salvage therapy.

CONDITIONS

Official Title

Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer

Who Can Participate

Age: 19Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male adults aged 19 years and older
  • Histologically confirmed prostate cancer
  • Castration-resistant prostate cancer
  • ECOG performance status of 2 or less
  • Previous exposure to docetaxel treatment
  • Available prostate specific antigen (PSA) level
  • Evaluable disease based on RECIST 1.1 criteria
Not Eligible

You will not qualify if you...

  • Diagnosis of other primary cancers within the past 3 years, except prostate cancer
  • History of organ transplantation
  • Hormone-sensitive prostate cancer
  • ECOG performance status of 3 or higher
  • No previous docetaxel exposure
  • Previous exposure to ifosfamide
  • No available PSA level
  • Disease not evaluable by RECIST 1.1 criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea

Seoul, South Korea

Actively Recruiting

Loading map...

Research Team

S

Sang Joon Shin

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here